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G1 cyclin-dependent kinases are sufficient to initiate DNA
synthesis in quiescent human fibroblasts
Lisa Connell-Crowley*, Stephen J. Elledge*† and J. Wade Harper*
Mammalian fibroblasts require mitogens in order to exit
from G0 (quiescence) and progress through the G1
phase of the cell cycle, although once they pass the
restriction point late in G1 they can enter S phase and
complete the cell cycle without mitogens [1]. Mitogenic
signals are integrated through the GTPase Ras, which
regulates the levels of cyclin D1 [2–5], a component of
the cell cycle machinery that operates during G1 phase
by activating cyclin-dependent kinase 4 (Cdk4). The
accumulation of active cyclin E–Cdk2 complexes also
requires Ras [6]. These two G1 cyclin–Cdk complexes act
on a family of E2F-associated transcriptional repressors
typified by the retinoblastoma protein (Rb) to bring
about a transcriptional program that promotes passage
through S phase [7–9], but can also activate DNA
replication independently of Rb–E2F [10–12]. Although
G1 cyclin–Cdk complexes are required for S-phase entry
and can shorten G1 phase when overexpressed [13–15],
it is not known whether they are sufficient for this
transition. Here, we report that serum-starved (G0)
diploid human fibroblasts initiate DNA synthesis upon
microinjection of active G1 cyclin–Cdk complexes, but
not upon microinjection of an S-phase cyclin–Cdk
complex. These data indicate that G1 Cdk activation is
rate-limiting for S-phase entry, and that Cdk activation is
likely to be the primary function of growth factor
signalling pathways that lead to DNA synthesis.
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Results and discussion
A microinjection approach, employing activated cyclin–Cdk
complexes made in insect cells, was used to examine
whether active G1 cyclin–Cdk complexes are sufficient to
initiate DNA replication in quiescent fibroblasts. In prin-
ciple, this approach should overcome the requirement of
mitogens for Cdk assembly [16] by providing the kinase in
a pre-activated form. Components of the G1 complexes
cyclin D1–Cdk4, cyclin E–Cdk2, and cyclin E–Cdk3, as
well as of the S-phase complex cyclin A–Cdk2, were co-
expressed in insect cells and purified to near homogeneity
as glutathione-S–transferase (GST) fusion proteins
(Figure 1a). The ability of the complexes to phosphorylate
Rb, the best characterized physiological substrate of these
kinases, was assessed in vitro. At a concentration of 6 nm,
cyclin E–Cdk2 preparations were the most active in phos-
phorylating Rb, whereas cyclin D1–Cdk4 preparations
were the least active (Figure 1b). These kinase prepara-
tions phosphorylate Rb on a subset of its in vivo phos-
phorylation sites, and phosphorylation of Rb by cyclin
D1–Cdk4 is sufficient to inactivate its growth suppression
function in a microinjection-based cell cycle assay [17].
Human diploid fibroblasts (WI38) were rendered quiescent
by serum starvation, and kinase complexes or the indicated
control proteins subsequently microinjected into the cyto-
plasm. Biotinylated rabbit immunoglobulin G (IgG) was
included in all injected samples to facilitate identification
of injected cells. After injection, cells were cultured with
bromodeoxyuridine (BrdU) for either 24 or 36 hours, fol-
lowed by immunofluorescence with anti-BrdU antibodies
to identify cells undergoing DNA synthesis, and with
Texas-red-conjugated streptavidin to identify injected cells
(Figure 2). Parallel uninjected cultures were supplemented
with 10% serum to assess the number of cells capable
of entering the cell cycle through mitogen-dependent
Figure 1
(a) Analysis of cyclin–Cdk complexes. GST–cyclin A–Cdk2 (lane 1),
GST–cyclin E–Cdk2 (lane 2), cyclin D1–GST–Cdk4 (lane 3), and
GST–cyclin E–Cdk3 (lane 5) were purified from insect cells using
glutathione–Sepharose [17]. Insect cell GST (lane 4), which binds to
the affinity matrix and is found as a contaminant in kinase preparations
(indicated by asterisk), was purified from uninfected cells for use as a
negative control. Proteins were concentrated to ~30 µM (of the limiting
subunit) in 50 mM Tris pH 7.5, 150 mM NaCl, using a Microcon-30
(Amicon). (b) The Rb kinase activity of cyclin–Cdk complexes was
determined using 60 or 6 nM kinase with 9 µM p56Rb in a 10 µl
reaction containing 20 mM Tris-HCl pH 7.5, 30 mM NaCl, 10 mM
MgCl2, and 40 µM [γ-32P]ATP for 40 min at 37°C. After SDS–PAGE,
products were visualized by autoradiography and quantitated by
phosphoimager analysis. At 60 nM, Rb phosphorylation was saturated
under the conditions used.
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pathways (Figures 2,3). Injection of cyclin E–Cdk2 or
cyclin D1–Cdk4 caused a significant number of cells to ini-
tiate DNA synthesis after 24 hours, compared with control-
injected cells (Figure 3). When cyclin E–Cdk2 was
injected, the extent of S-phase entry ranged from 17 to
32% using two independent preparations of kinase in four
independent injection experiments (Figures 2,3 and data
not shown). In contrast, less than 3% of cells initiated DNA
replication after 24 hours upon injection of either rabbit
IgG alone or insect cell GST alone. Less than 1% of un-
injected cells labeled with BrdU. Surprisingly, the extent
of BrdU incorporation was substantially higher than that
observed with serum-mediated cell-cycle entry, which
ranged from 8 to 12% at 24 hours under these conditions.
Consistent with the result of studies that used cell lines
harboring inducible cyclin E [13], injection of cyclin E
alone did not induce DNA replication significantly above
the levels found with GST alone (data not shown).
Upon injection of cyclin D1–Cdk4, the range of S-phase
entry (14–27% using two kinase preparations) was compa-
rable to that found with cyclin E–Cdk2 (Figures 2,3). Pre-
vious studies have shown that the individual effects of
cyclin D1 and cyclin E overexpression on the rate of
S-phase entry from quiescence are additive [13]. Similarly,
we found that injection of a mixture of cyclin E–Cdk2 and
cyclin D1–Cdk4 resulted in an even greater proportion
(31–47%) of cells entering S phase than injection of either
kinase alone, comparable to the sum of the effects of each
individual kinase in each experiment (Figure 3a,b). This
additive effect is most likely to reflect simply higher kinase
levels: we did not find evidence for synergy under any con-
ditions tested. We cannot, however, rule out the possibility
that quiescent cells display two regulatory states, one com-
petent for cyclin E–Cdk2-mediated S-phase entry, and the
other competent for cyclin D1–Cdk4-mediated entry. In
this case, an additive effect would reflect cell-cycle entry
by both populations. As expected, the fraction of injected
cells undergoing DNA synthesis upon cyclin–Cdk injec-
tion was more at the 36 hour time point (30–49% BrdU-
positive cells) than at the 24 hour time point (Figure 3a).
In our initial experiments, we used kinase concentrations
which, when introduced into the cells, would exceed the
normal levels in cycling fibroblasts. The rationale for this
was to overcome inhibitory barriers set up in quiescent
cells, such as might be produced by the presence of excess
Cdk inhibitors. Cycling WI38 cells contain approximately
0.2 × 106 molecules of Cdk2 [18]. By injecting 10 µM
kinase complexes, we estimate that, on average,
0.6–1.2 × 106 molecules of kinase are delivered to each
cell. To examine the effects of more physiological levels of
Cdk–cyclin complexes on entry into S phase from quies-
cence, a titration experiment was performed (Figure 3d).
Injection of 2.5 µM cyclin D1–Cdk4 or cyclin E–Cdk2 — a
concentration similar to the endogenous levels of Cdk2 —
also led to S-phase entry in 5–8% of cells. A comparable
fraction of cells underwent DNA synthesis in response to
serum in this experiment (8%; Figure 3d). Thus, the levels
of active Cdks required to induce DNA replication in qui-
escent fibroblasts are comparable to those found in cycling
cells. At the highest level of injected Cdk complexes, we
routinely found additive effects when cyclin D1–Cdk4 and
cyclin E–Cdk2 were coinjected (Figure 3a,b,d), but at
lower levels of injected kinase (Figure 3d) a strict additive
effect was not observed. Although the reason for this is not
clear, it may reflect a requirement for a certain threshold
level of kinase for S-phase entry. In this regard, a signifi-
cant fraction of the injected kinase (20–50%) fails to
translocate to the nucleus 24 hours after injection (data not
shown), and the kinetics and efficiency of nuclear uptake
may not be linear at lower concentrations.
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Figure 2
Visualization of DNA replication in cyclin–Cdk-
injected quiescent fibroblasts by fluorescence
microscopy. Mid-passage (14–20 doublings)
normal diploid human fibroblast (WI38) cells
were seeded at 50–70% confluence in
Dulbecco’s modified Eagle’s medium (DMEM)
plus 10% fetal calf serum (FCS). At 95%
confluence, cells were washed with PBS and
incubated for 4 days in DMEM plus 0.1%
FCS. Cytoplasmic microinjections of the
indicated proteins were performed using an
Eppendorf micromanipulator and microinjector
with femtotip capillary micropipets as
described [17]. After injection, cells were
labeled with 10 µM BrdU in media containing
0.1% FCS for 24 or 36 h. To measure serum-
dependent DNA synthesis, control cells were
stimulated with 10% serum in the presence of
BrdU. Cells were co-immunostained with
Texas-red–streptavidin (red) to visualize the
injection marker (biotinylated rabbit IgG), and
anti-BrdU followed by flourescein-conjugated
anti-mouse IgG to visualize BrdU incorporation
(green). Cells were also stained with DAPI
(blue) to visualize nuclei. For the panels of
uninjected and cyclin A–Cdk2-injected cells,
fields were selected to show a rare BrdU-
labeled cell found in < 3% of injected cells.
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Previous studies have suggested that Cdk3 and Cdk2 play
distinct roles in S-phase entry [19,20]. For example, a
dominant-negative form of Cdk3 blocks cell-cycle pro-
gression in G1 and this arrest cannot be overcome by
expression of Cdk2, and vice versa [19]. Although endoge-
nous cyclin activators of Cdk3 have not been identified,
cyclin E is a candidate: Cdk3 is thought to function at a
time when cyclin E levels are maximal [19], and cyclin E
can activate Cdk3 in insect cells [18]. We investigated
whether induction of cell-cycle entry by cyclin E was spe-
cific to Cdk2, and found that cyclin E–Cdk3 could also
induce replication in quiescent cells. Injection of cyclin
E–Cdk3 led to S-phase entry in approximately 33% of
injected cells after 24 hours, compared with 6% BrdU-pos-
itive cells in the presence of serum, and 1% in IgG-
injected cells (Figure 3c). The extent of S-phase entry
observed with cyclin E–Cdk3 was comparable to that
observed with cyclin D1–Cdk4 injection (28%) in the
same experiment. 
There is evidence in the literature supporting the idea
that cyclins can function in a redundant manner. For
example, cyclin A, which has major roles in S and G2
phases, can override Rb-mediated cell-cycle arrest in G1
when overexpressed [21]. In yeast, the S-phase cyclin
Clb5, as well as human cyclins A, B, C, D and E, can all
complement deletions in the three CLN genes that encode
G1 cyclins. Unlike cyclin E–Cdk2, however, active cyclin
A–Cdk2 complexes (Figure 1b) were unable to induce
S-phase entry in quiescent fibroblasts (Figure 3c). It was
possible that cyclin A–Cdk2 could perform some, but not
all, of the stimulatory functions required for S-phase entry;
we therefore examined whether a stimulatory role for
cyclin A–Cdk2 could be revealed by co-injection with
cyclin D1–Cdk4. Whereas the effects of cyclin E–Cdk2
and cyclin D1–Cdk4 were additive, co-injection of cyclin
A–Cdk2 with cyclin D1–Cdk4 did not increase the level of
S-phase entry above that of cyclin D1–Cdk4 alone
(Figure 3c). We and others have previously shown that
cyclin A–Cdk2 complexes bind to the CIP/KIP family of
Cdk inhibitors with an affinity, as measured by kinase
inhibition, similar to that of cyclin E–Cdk2 [18,22,23].
The finding that cyclin A–Cdk2 does not induce S-phase
entry argues that Cdk inhibitor sequestration is not suffi-
cient to activate DNA replication in this setting.
Previous studies point to a central role for Ras and related
GTPases in coordinating the alterations in transcription
and cellular architecture that facilitate mitogen-dependent
exit from quiescence and entry into S phase. Microinjec-
tion of activated forms of Ras, Rac, and Cdc42 (but not
wild-type proteins) can induce DNA synthesis in quies-
cent mouse fibroblasts [24,25], and neutralizing antibodies
against Ras block DNA synthesis induced by mitogens
[2,3]. Ras can activate Rac and Rho, and is required for the
induction of cyclin D1 expression during early G1 [2–5]:
induction of cyclin D1 is required for S-phase entry in Rb-
expressing cells. Ras activation also leads to increased
levels of cyclin E–Cdk2 activity, perhaps through the
modulation of CDK inhibitors [6]. Thus, although Cdk
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Figure 3
Injection of G1 cyclin–Cdk complexes, but not an S-phase complex,
induces quiescent cells to initiate DNA synthesis. (a–d) The results of
four independent microinjection experiments employing cyclin E–Cdk2
(a,b,d), cyclin D1–Cdk4 (a–d), cyclin E–Cdk3 (c), cyclin A–Cdk2 (c)
and the indicated control proteins as shown. Kinases were diluted to
10 µM in injection buffer containing biotinylated rabbit IgG (1 mg/ml)
prior to injection, except in (d), where kinases were diluted to 10, 5, or
2.5 µM prior to injection. Cells were immunostained to visualize the
IgG and BrdU (see Figure 2), prior to analysis by fluorescence
microscopy. The number of cells counted with each protein ranged
from 91–138, 49–119, 62–105, and 64–93 for experiments 1 to 4,
respectively. The number of uninjected and serum-stimulated cells
counted in each experiment ranged from 204–247.
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activation is clearly linked with Ras activation, it is not
clear whether Cdk activation is the major rate-limiting
event in S-phase entry induced by mitogens, or whether
other mitogen-mediated signals are also required. 
Here, we show that the mitogen requirement for S-phase
entry in normal diploid human fibroblasts can be bypassed
by the microinjection of previously activated cyclin
D1–Cdk4, cyclin E–Cdk2 or cyclin E–Cdk3, but not by
the S-phase kinase, cyclin A–Cdk2. Thus, pathways
leading to G1 cyclin-kinase activation — either through
cyclin induction, complex assembly, or Cdk inhibitor
down-regulation — appear to constitute the primary rate-
limiting event in the DNA synthesis signalling pathway
coordinated by mitogens. Among cell-cycle control ele-
ments, the only other protein that has been shown to
induce replication in quiescent rodent fibroblasts is E2F-1
[26]. When quiescent cells were microinjected with an
E2F-1-expressing plasmid, 14–24% entered S phase, a
level similar to that observed here with cyclin–Cdk
protein injection. The ability of cyclin D1–Cdk4 to induce
DNA synthesis in quiescent fibroblasts may reflect, at
least in part, its ability to phosphorylate Rb, and perhaps
Rb-related ‘pocket’ proteins. Such activity would be
expected to initiate a transcriptional program compatible
with S-phase progression, including cyclin E induction
through Rb phosphorylation [9]. Although the expression
of cyclin E in quiescent cells is not sufficient for full Cdk2
activation in the absence of serum [13], cyclin D1–Cdk4
may generate a regulatory state that facilitates cyclin
E–Cdk2 activation and a role for cyclin E in cyclin D1-
mediated cell-cycle entry cannot be excluded. In contrast,
the finding that cyclin E expression can activate DNA
synthesis in the absence of Rb phosphorylation [10,11]
and E2F activation [10,27] suggests that the effects
observed here with cyclin E–Cdk2 may be Rb-indepen-
dent. This suggestion is strengthened by the finding that
phosphorylation of Rb by cyclin E–Cdk2 in vitro is not
sufficient to inactivate the growth suppressive activity of
Rb in a microinjection-based cell-cycle assay, whereas
cyclin D1–Cdk4 can regulate Rb in this assay [17].
Regardless of the mechanisms involved, our results point
to G1 cyclin-kinases as rate-limiting downstream com-
ponents in the signal transduction pathway leading from
the cell surface to DNA synthesis.
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